Figure 3From: Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situChanges in biomarkers before and after lapatinib. pHER2, phospho human epidermal growth factor receptor 2; pERK1, phosphor extracellular-regulated kinase 1.Back to article page